Soleno Therapeutics' DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome Patients

In this article:
  • Soleno Therapeutics Inc (NASDAQ: SLNO) has announced the presentation of behavioral outcomes data from its ongoing open-label extension study (C602) of DCCR (diazoxide choline) for Prader-Willi Syndrome (PWS).

  • Prader-Willi Syndrome is characterized by a chronic feeling of insatiable hunger that severely diminishes the quality of life.

  • Data were presented at the Pediatric Academic Societies (PAS) 2021 Virtual Annual Meeting.

  • Through the 48 interviews, 39 behavioral outcomes were identified in seven outcome domains, with an average of 22±5.9 behaviors reported.

  • The three most frequently reported domains were Food-seeking Behaviors, Mealtime Behaviors, and Daily Life Behaviors.

  • 83% of the participants reported a positive change in one or more behavioral outcomes on DCCR, more than 70% reported positive changes in one quarter or more of behaviors. In comparison, 48% reported positive changes in more than half of behaviors.

  • 23% of participants reported a negative behavior change, and 6% reported more than one negative change

  • Price Action: SLNO shares are down 0.8% at $1.18 in the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement